everolimus eluting stent trial summary

Coronary artery disease

All type of patient: 11 trials - FUTURE I - FUTURE II - SPIRIT I - SPIRIT II - SPIRIT IV - SPIRIT III - LEFT-MAIN-2 - SORT OUT IV - PLATINUM - ISAR-TEST 4 (EES vs SES) - RESET

No demonstrated result

suggested myocardial infarction (fatal and non fatal) by 39% (not demonstrated)

suggested MACE by 40% (not demonstrated)

suggested target-vessel revascularization by 33% (not demonstrated)

suggested 2 yr TLR by 35% (not demonstrated)

suggested target lesion revascularisation by 44% (not demonstrated)

suggested Stent thrombosis (any, end of follow up) by 63% (not demonstrated)

No demonstrated result

See more clinical conditions

All type of patients: 13 trials - FUTURE I - FUTURE II - SPIRIT I - SPIRIT II - SPIRIT IV - SPIRIT III - LEFT-MAIN-2 - SORT OUT IV - COMPARE - PLATINUM - ISAR-TEST 4 (EES vs SES) - BASKET-PROVE (EES) - RESET

No demonstrated result

suggested target-vessel revascularization by 64% (not demonstrated)

No demonstrated result

suggested myocardial infarction (fatal and non fatal) by 42% (not demonstrated)

suggested MACE by 40% (not demonstrated)

suggested 2 yr MACE by 34% (not demonstrated)

suggested target-vessel revascularization by 42% (not demonstrated)

suggested 2 yr TLR by 35% (not demonstrated)

suggested target lesion revascularisation by 50% (not demonstrated)

suggested Stent thrombosis (any, end of follow up) by 69% (not demonstrated)

suggested 4y stent thrombosis (ARC) by 61% (not demonstrated)

suggested sub acute stent thrombosis (1-30 days) by 90% (not demonstrated)

No demonstrated result

Diabetic patients : 1 trials - ESSENCE diabetes

No demonstrated result

Small vessels: 1 trials - SPIRIT III (small vessel subgroup)

No demonstrated result

suggested MACE by 74% (not demonstrated)

suggested target-vessel revascularization by 80% (not demonstrated)

suggested target lesion revascularisation by 90% (not demonstrated)

Unparticular patients: 9 trials - FUTURE I - FUTURE II - SPIRIT I - SPIRIT II - SPIRIT IV - SPIRIT III - SORT OUT IV - COMPARE - ISAR-TEST 4 (EES vs SES)

No demonstrated result

suggested myocardial infarction (fatal and non fatal) by 42% (not demonstrated)

suggested MACE by 40% (not demonstrated)

suggested 2 yr MACE by 34% (not demonstrated)

suggested target-vessel revascularization by 42% (not demonstrated)

suggested 2 yr TLR by 35% (not demonstrated)

suggested target lesion revascularisation by 50% (not demonstrated)

suggested Stent thrombosis (any, end of follow up) by 69% (not demonstrated)

suggested 4y stent thrombosis (ARC) by 61% (not demonstrated)

suggested sub acute stent thrombosis (1-30 days) by 90% (not demonstrated)

No demonstrated result

Unprotected left main artery stenosis: 1 trials - LEFT-MAIN-2

No demonstrated result

Stable angina

All type of patient: 10 trials - FUTURE I - FUTURE II - SPIRIT I - SPIRIT II - SPIRIT IV - SPIRIT III - LEFT-MAIN-2 - SORT OUT IV - COMPARE - ISAR-TEST 4 (EES vs SES)

No demonstrated result

suggested myocardial infarction (fatal and non fatal) by 42% (not demonstrated)

suggested MACE by 40% (not demonstrated)

suggested 2 yr MACE by 34% (not demonstrated)

suggested target-vessel revascularization by 42% (not demonstrated)

suggested 2 yr TLR by 35% (not demonstrated)

suggested target lesion revascularisation by 50% (not demonstrated)

suggested Stent thrombosis (any, end of follow up) by 69% (not demonstrated)

suggested 4y stent thrombosis (ARC) by 61% (not demonstrated)

suggested sub acute stent thrombosis (1-30 days) by 90% (not demonstrated)

No demonstrated result

Everolimus eluting stent Drug eluting stent

XIENCE 5 - Abbott XIENCE V - Guidant XIENCE V - XIENCE V

Coronary artery disease

Stable angina